Homology Medicines, Inc. announced that Alise Reicin, M.D., has been appointed to its Board of Directors. Dr. Reicin is the President, Global Clinical Development at Celgene Corporation where she is responsible for mid- to late-stage clinical development across Celgene’s portfolio and is a member of the company’s Executive Committee. Dr. Reicin’s industry experience spans more than 25 years with leadership roles at Merck and Merck KGaA’s biopharmaceutical business, EMD Serono. Among her many accomplishments in directing initial clinical development and regulatory filings worldwide, Dr. Reicin’s leadership contributed to the first approval of KEYTRUDA® in the United States. Prior to her role at Celgene, Dr. Reicin was the Senior Vice President, Head of Global Clinical Development at EMD Serono where she led both early and late clinical development across their entire portfolio. The Company also announced that Cameron Wheeler, Ph.D., Partner at Deerfield and a member of Homology’s Board since 2017, has stepped down from the Board.